export default {
	en: {
		app: {
			name: 'ASH Microsite 2023',
		},
		home: {
			title: 'Our<br />Pipeline',
			footer: {
				jobCode: 'UNB-EM-0239 November 2023',
				copyright: '&copy; 2023 Regeneron Pharmaceuticals, Inc. All Rights Reserved.',
			},
		},
		titles: {
			trials: {
				lymphoma: 'Lymphoma',
				myleoma: 'Myleoma',
				'classical-hematology': 'Classical Hematology',
				'solid-tumor': 'Solid Tumor',
			},
			cards: {
				'olympia-2':
					'<strong>OLYMPIA-2</strong> Odronextamab (CD20xCD3 Bispecific) + Chemotherapy',
				'olympia-5':
					'<strong>OLYMPIA-5</strong> Odronextamab (CD20xCD3 Bispecific) + Chemotherapy',
				'olympia-1': '<strong>OLYMPIA-1</strong> Odronextamab (CD20xCD3 Bispecific)',
				'olympia-3':
					'<strong>OLYMPIA-3</strong> Odronextamab (CD20xCD3 Bispecific) + Chemotherapy',
				'olympia-4': '<strong>OLYMPIA-4</strong> Odronextamab (CD20xCD3 Bispecific)',
				'elm-2': '<strong>ELM-2</strong> Odronextamab (CD20xCD3 bispecific)',
				'elm-1': '<strong>ELM-1</strong> Odronextamab (CD20xCD3 bispecific)',
				'athena-1':
					'<strong>ATHENA-1</strong> Odronextamab (CD20xCD3 bispecific) + REGN5837 (CD22xCD28 bispecific)',
				'clio-1':
					'<strong>CLIO-1</strong> Odronextamab (CD20xCD3 bispecific) + Cemiplimab (PD-1 monoclonal)',
				orchid: '<strong>ORCHID</strong> Non-interventional real-world experience',
				flora: '<strong>FLORA</strong> Non-interventional real-world experience',
				'linker-mm3': '<strong>LINKER-MM3</strong> Linvoseltamab (BCMAxCD3 bispecific)',
				'linker-mm4': '<strong>LINKER-MM4</strong> Linvoseltamab (BCMAxCD3 bispecific)',
				'linker-mm1': '<strong>LINKER-MM1</strong> Linvoseltamab (BCMAxCD3 bispecific)',
				'linker-smm1': '<strong>LINKER-SMM1</strong>  Linvoseltamab (BCMAxCD3 bispecific)',
				'linker-mm2':
					'<strong>LINKER-MM2</strong> Linvoseltamab (BCMAxCD3 bispecific) + Other Cancer Treatments',
				nct05673967:
					'<strong>NCT05673967</strong> Non-interventional real-world experience',
				'access-1':
					'<strong>ACCESS-1</strong> Pozelimab (C5 monoclonal) + Cemidiran (C5 RNAi)',
				nct04409080: '<strong>NCT04409080</strong> REGN7257 (IL2RG blocking antibody)',
				nct05618808: '<strong>NCT05618808</strong> REGN9933 (Factor XI Antibody)',
				nct04601051: '<strong>NCT04601051</strong> NTLA-2001 (Gene editing)',
				nct05481333: '<strong>NCT05481333</strong> REGN7999 (TMPRSS6 antagonist)',
				'honey-b': '<strong>HONEY-B</strong> Lead in, non-interventional study',
				'pd-1-monoclonal-p3': 'Cemiplimab (PD-1 monoclonal)',
				'pd-1-monoclonal-p2': 'Cemiplimab (PD-1 monoclonal)',
				'pd-1-monoclonal-p1': 'Cemiplimab (PD-1 monoclonal)',
				'pd-1-monoclonal-non-interventional': 'Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-lung-cancer-01':
					'Fianlimab (LAG-3 monoclonal) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-lung-cancer-02':
					'Fianlimab (LAG-3 monoclonal) + Cemiplimab (PD-1 monoclonal) + Chemotherapy',
				'solid-tumor-lung-cancer-03':
					'Ipilimumab (CTLA-4 monoclonal) + Cemiplimab (PD-1 monoclonal) + Chemotherapy',
				'solid-tumor-lung-cancer-04': 'REGN5093 (METxMET biparatopic)',
				'solid-tumor-lung-cancer-05': 'REGN5093-M114 (METxMET biparatopic ADC)',
				'solid-tumor-melanoma-01':
					'Fianlimab (LAG-3 monoclonal) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-melanoma-02':
					'Fianlimab (LAG-3 monoclonal) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-prostate-01':
					'REGN4336 (PSMAxCD3 bispecific) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-prostate-02':
					'REGN5678 (PSMAxCD28 bispecific) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-ovarian-01':
					'Ubamatamab (MUC16xCD3 bispecific) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-ovarian-02':
					'REGN5668 (MUC16xCD28 bispecific) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-ovarian-03':
					'REGN5668 (MUC16xCD28 bispecific) + Ubamatamab (MUC16xCD3 bispecific)',
				'solid-tumor-multiple-tumors-01':
					'REGN7075 (EGFRxCD28 bispecific) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-multiple-tumors-02':
					'Vidutolimod (TLR9 agonist) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-multiple-tumors-03':
					'Fianlimab (LAG-3 monoclonal) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-multiple-tumors-04': 'Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-multiple-tumors-05':
					'REGN6569 (GITR monoclonal) + Cemiplimab (PD-1 monoclonal)',
				'solid-tumor-multiple-tumors-06':
					'89Zr-DFOREGN5054 (CD8 monoclonal) + Cemiplimab (PD-1 monoclonal)',
			},
			cardsSection: {
				'skin-cancer': 'non-melanoma skin cancer',
				'lung-cancer': 'Non-Small Cell Lung CancerÂ ',
				melanoma: 'Melanoma',
				prostate: 'Prostate',
				ovarian: 'Ovarian',
				'multiple-tumors': 'multiple tumors',
			},
		},
		misc: {
			clinicalTrials: 'Clinical trials',
			explore: 'Explore',
			back: 'Back',
			backToTrials: 'Back To Trials',
			phase: 'Phase',
			nonInterventional: 'Non-Interventional',
			seeTrialInfo: 'See Trial Info',
			seeClincialGov: 'Visit ClinicalTrials.gov',
			noPdf: 'No Trial card PDF found. Please try again later.',
			close: 'Close',
		},
		trials: {
			overlay: {
				lymphoma: 'LEARN ABOUT ODRONEXTAMAB',
				myleoma: 'LEARN ABOUT linvoseltamab',
			},
			footer: {
				meta: 'Odronextamab is an investigational drug and has not been fully evaluated by any regulatory authority.',
				jobCode: 'UNB-EM-0239. November 2023',
				enclosed:
					'The enclosed materials are being provided in response to your unsolicited request and are for your information only. The product discussed herein is an investigational agent and has not been fully evaluated or approved by the US Food and Drug Administration or any other regulatory agency worldwide. Reactive Use Only.',
				copyright: '&copy; 2023 Regeneron Pharmaceuticals, Inc. All Rights Reserved.',
			},
		},
	},
};
